Volume Is Not a Care Model: What the Done Verdict and the LifeMD Allegations Mean for Prescribers

The problems with volume-driven telehealth are no longer a matter of opinion. In the past year they have been documented by a federal jury, by former employees speaking on the record, and by peer-reviewed research. Each account describes the same failure from a different angle: when a platform's revenue depends on how many prescriptions it moves, clinical judgment becomes the cost of doing business. This post walks through what happened, why pharmacy partnerships make it worse, and how PEPTPlus is built against that model.

A federal jury drew the line

A federal jury in San Francisco convicted the founder and CEO of Done, a digital health company, along with its clinical president, for a years-long scheme to illegally distribute Adderall over the internet and to commit health care fraud. According to the Department of Justice, the company's subscription model limited initial screening appointments to less than half the length of a typical psychiatric evaluation, and its compensation structure paid clinicians to refill prescriptions without any clinical interaction with the patient. Prosecutors described more than 37 million pills distributed and more than $12 million in fraudulent insurance claims. The CEO was later sentenced to six years in prison.

The case matters beyond its facts. It was the first federal drug-distribution prosecution of a telehealth company, and DOJ used it to send a message: platforms that engineer their product, their protocols, and their pay structure around volume and revenue rather than clinical judgment are a criminal-enforcement target, not just a licensing problem. Law firms advising the sector read it the same way; Ropes & Gray's analysis of the expanded criminal risk for telehealth platforms, MSOs, and investors is worth reading in full.

The allegations did not stop with stimulants

In July, STAT reported that former employees of LifeMD, a publicly traded telehealth company that prescribes GLP-1 weight-loss medications, allege the company pressed clinicians to see more patients and issue prescriptions faster, with little screening and follow-up. Two former workers described providers being expected to review roughly 25 cases per hour from intake forms alone, about two minutes per patient. The company strenuously denies the allegations, and no finding has been made against it. But the shape of the complaint is familiar: a growth target on one side, a clinician's judgment on the other, and a business model that only works if judgment yields.

The research says this is structural, not anecdotal

Direct-to-consumer telehealth has a measurable prescribing problem. A study published in Pediatrics found that antibiotics were prescribed in 52% of DTC telehealth visits for children's respiratory infections, compared with 42% of urgent-care and 31% of primary-care visits, and that guideline concordance was worse in the telehealth group. Earlier work found that in a DTC telemedicine system, receiving an antibiotic prescription was the single factor most strongly associated with patient satisfaction, more than any other patient or physician variable. The Lown Institute's summary of this evidence, Could telehealth increase inappropriate prescribing?, states the mechanism plainly: companies focused on keeping satisfaction scores high will go against clinical guidelines to give patients what they came for.

The lesson generalizes well beyond antibiotics. If the platform is paid per prescription, or measures its clinicians on throughput and satisfaction, the prescription becomes the product. Every safeguard that slows a prescription down, a longer intake, a declined refill, a request for labs, is a cost the model is designed to minimize.

Pharmacy partnerships compound the problem

Less discussed, but just as important for prescribers, is what happens on the pharmacy side of these arrangements. Many compounding pharmacies court providers with catalog discounts, tiered pricing, and volume-based perks. Whatever the intent, the effect is to turn the clinician into a sales channel for a particular pharmacy's catalog. That is the opposite of personalized medicine, and it puts the provider in an uncomfortable position under the Anti-Kickback Statute and its state analogs, which we covered in our guide to prescribing compounded semaglutide in 2026.

The contracts are the other half of the story. Before you sign a dropship or fulfillment agreement, read the sections on refunds, chargebacks, and patient complaints closely. Some fulfillment agreements move part of those costs to the prescriber, even though the pharmacy compounded the product, labeled it, and shipped it. Whether or not yours does, it is worth knowing before a dispute arrives. A pharmacy that takes the margin but disclaims the risk is behaving like the volume platforms it supplies: monetizing prescriptions while offloading responsibility for what happens to the patient.

How PEPTPlus is built against that model

We designed PEPTPlus starting from the incentives, because incentives are where every one of the cases above went wrong.

No per-prescription revenue. PEPTPlus charges a flat monthly subscription to providers and to pharmacies, and takes $0 on the drug charge. Our revenue does not go up when you prescribe more, and it does not go down when you decline a refill. We have no reason to measure you on throughput, and we don't.
The prescriber's judgment is the only judgment. PEPTPlus does not script your intake, score your patients' satisfaction, or set productivity targets. You evaluate your patient in your own practice, under your own standard of care, and prescribe when you decide it is appropriate. The platform routes that prescription; it never generates one.
No catalog discounts, no steering. Prescriptions are matched to a licensed pharmacy by neutral, rules-based criteria: verified quality (COA-backed batches), price, and delivery reliability, limited to pharmacies licensed in the patient's state. Pharmacies set their own prices. Their subscription tier does not enter the matching criteria; the higher pharmacy tier adds the ingredient-sourcing marketplace and priority support, not priority placement. The patient does not see which pharmacy was matched until fulfillment. There is no mechanism for a pharmacy to reward you for choosing its catalog, because you don't choose its catalog.
Liability sits where the responsibility is. Under our Pharmacy Marketplace Terms, the dispensing pharmacy is the dispenser of record and bears sole professional, legal, and regulatory responsibility for the prescription it fills, the compound, the label, the product, and its delivery to the patient (Section 2.3), including recalls (Section 3.6). The pharmacy is solely responsible for patient refunds, returns, disputes, and chargebacks relating to its products and fills (Section 5.6). Under the Provider Terms, you remain the prescriber of record with sole clinical authority for each prescription. You are responsible for the prescription; the pharmacy is responsible for the fill.
Provenance and outcomes, not just fulfillment. Every batch carries a certificate of analysis, and you can see exactly what your patient received and from which pharmacy. That is the information a careful prescriber needs, and it is also what a regulator asks for first.

What to ask any platform or pharmacy you work with

If you prescribe through a telehealth platform or a compounding pharmacy today, five questions will tell you which model you are in.

How does the company make money when I prescribe, and does it make more when I prescribe more?
Am I measured on visit length, throughput, refill rate, or patient satisfaction?
Does the pharmacy offer me pricing or perks that depend on how much of its catalog I order?
Who is contractually responsible for refunds, chargebacks, and complaints about the product?
Can I see the certificate of analysis for the batch my patient received?

The honest answers to those questions are the difference between infrastructure that supports clinical judgment and infrastructure that consumes it. PEPTPlus was built to give you the first kind. If that is how you want to prescribe, you can start prescribing on PEPTPlus, or read more about how we work with pharmacies.